Showing 1621-1630 of 5960 results for "".
New OTC Topicals Target Hyperpigmentation, Melasma
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-otc-topicals-target-hyperpigmentation-melasma/22081/There's a new and expanding menu of options to improve uneven tone, proving that OTCs can provide benefit for a vexing concern.2018 Therapeutics and Device Highlights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-2018-therapeutics-and-device-highlights/18374/2018 saw new approvals and clearances for acne, impetigo, psoriasis, and skin cancer from Ortho Dermatologics, Sun Pharma, Cutanea, and more. Plus, updates for Restylane, new devices from BTL, Cutera, and others.A Growing Armamentarium for Psoriasis: How to Choose the Right Treatment for Each Patient
https://practicaldermatology.com/topics/psoriasis/a-growing-armamentarium-for-psoriasis-how-to-choose-the-right-treatment-for-each-patient/18214/Erin Boh, MD joins host Joshua Zeichner, MD in this edition of DermTube Journal Club to offer tips for navigating all the new and existing treatment options for patients with moderate to severe psoriasis. With so many effective options on the market, Dr. Boh says it's possible to find the best fit fFinding and Taking Advantage of Your Employees' Strengths
https://practicaldermatology.com/topics/practice-management/finding-and-taking-advantage-of-your-employees-strengths/20435/Tips for successfully incorporating a strength-based approach to staff management.Dupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sThe Menassaince
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-menassaince/18722/Men are an increasingly important demographic in aesthetics today, Steven Dayan, MD tells Dermtube host Joel Cohen, MD. Unlike their female counterparts, men tend to prefer one-and-done procedures and often seek treatment after hours, he says.Updates on NMSC, Zika, Aesthetics from Summer AAD Meeting
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-updates-on-nmsc-zika-aesthetics-from-summer-aad-meeting/18735/From the dermatologist's role in preparing for Zika to the latest advancements in aesthetics, the Summer meeting of the American Academy of Dermatology in Boston offered fresh insights for practitioners. Get updates on AK Management, the Zika risk, dermatologic care for nursing mothers, fillers, andAvoid Financial Gridlock when Partners Disagree
https://practicaldermatology.com/topics/practice-management/avoid-financial-gridlock-when-partners-disagree/20980/Three ideas for every group practice.BONT-A Extends Fillers; Almirall to Acquire Thermi
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-bont-a-extends-fillers-almirall-to-acquire-thermi/18648/In this edition of DermWireTV, a look at new data showing that injections with botulinum neurotoxin can extend the efficacy of hyaluronic acid fillers. The American Academy of Dermatology Association offers more response to the USPSTF draft recommendation on the benefits of skin exams for melanoma.11 Tactical Errors to Avoid in Your Dermatology Social Media Strategy
https://practicaldermatology.com/topics/practice-management/11-tactical-errors-to-avoid-in-your-dermatology-social-media-strategy/21066/Tactical mistakes can dilute the impact of your overall social media effort.